Turning Point Benefit Group’s Biogen BIIB Stock Holding History

Turning Point Benefit Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3	Closed	-$527	–	179
2025 Q4	$527	Hold	3	–	–	﹤0.01%	632
2025 Q3	$462	Buy	+3	New	+$406	﹤0.01%	509

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Turning Point Benefit Group's BIIB Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Biogen (BIIB) in Q1 2026, closing a stake of 3 shares — an estimated $527 sold.

Turning Point Benefit Group first reported a position in BIIB in Q3 2025 and held it in 2 quarters. The position peaked at $527 in Q4 2025. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Turning Point Benefit Group reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
Turning Point Benefit Group sold 3 Biogen shares in Q1 2026, an estimated $527.
Turning Point Benefit Group first reported a position in Biogen in Q3 2025 and held it in 2 quarters.
Turning Point Benefit Group's Biogen position peaked at $527 in Q4 2025.
1,009 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.